Orphan Indications for CD19 Redirected Autologous T Cells

This study is testing a type of immune cell therapy (using reprogrammed T cells that target the CD19 protein) for rare and difficult-to-treat forms of a blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The trial focuses on specific genetic subtypes of this leukemia. **You may be eligible if...** - You have been diagnosed with CD19-positive B-ALL (a type of leukemia) - Your leukemia has a specific chromosome abnormality — either fewer than 45 chromosomes (hypodiploid) or a specific chromosomal rearrangement (t(17;19)) - You are enrolled in either Cohort A or Cohort B of the study **You may NOT be eligible if...** - You do not have the specific genetic abnormalities required - You are unable to give informed consent - You have other medical conditions that prevent safe treatment Talk to your doctor to see if this trial is right for you.